0001127602-24-006213.txt : 20240221 0001127602-24-006213.hdr.sgml : 20240221 20240221212830 ACCESSION NUMBER: 0001127602-24-006213 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240216 FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Murphy Nicole CENTRAL INDEX KEY: 0001910644 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19311 FILM NUMBER: 24662043 MAIL ADDRESS: STREET 1: BIOGEN INC. STREET 2: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 7814642000 MAIL ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC. DATE OF NAME CHANGE: 20070427 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2024-02-16 0000875045 BIOGEN INC. BIIB 0001910644 Murphy Nicole 225 BINNEY STREET CAMBRIDGE MA 02142 1 Head of Pharm Ops and Tech 0 Common Stock 2024-02-16 4 M 0 856 0 A 9623.9895 D Common Stock 2024-02-16 4 F 0 414 219.08 D 9209.9895 D Common Stock 2024-02-16 4 M 0 404 0 A 9613.9895 D Common Stock 2024-02-16 4 F 0 196 219.08 D 9417.9895 D Performance Stock Unit 0 2024-02-16 4 M 0 856 0 D 2024-02-18 2024-02-18 Common Stock 856 0 D Restricted Stock Unit 0 2024-02-16 4 M 0 404 0 D 2024-02-18 Common Stock 404 504 D Restricted Stock Unit 0 2024-02-16 4 J 0 504 0 D 2024-02-18 Common Stock 504 0 D This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. /s/ Wendell Taylor, attorney in fact for Nicole Murphy 2024-02-21